Exicure, Inc. (NASDAQ:XCUR - Get Free Report) shares fell 4.5% on Monday . The company traded as low as $9.77 and last traded at $10.04. 4,221 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 574,559 shares. The stock had previously closed at $10.51.
Exicure Trading Up 0.5%
The stock's fifty day moving average price is $11.16 and its two-hundred day moving average price is $12.62. The firm has a market capitalization of $61.73 million, a price-to-earnings ratio of -4.72 and a beta of 3.86.
Exicure (NASDAQ:XCUR - Get Free Report) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($3.39) earnings per share for the quarter.
Institutional Investors Weigh In On Exicure
An institutional investor recently bought a new position in Exicure stock. Geode Capital Management LLC acquired a new stake in Exicure, Inc. (NASDAQ:XCUR - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 12,645 shares of the company's stock, valued at approximately $173,000. Geode Capital Management LLC owned approximately 0.48% of Exicure at the end of the most recent quarter. 42.82% of the stock is currently owned by institutional investors and hedge funds.
Exicure Company Profile
(
Get Free Report)
Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.
Recommended Stories
Before you consider Exicure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exicure wasn't on the list.
While Exicure currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
